share_log

NeuroSense Reports Results From 12-Month Analysis Of Its PARADIGM Phase 2b Study Evaluating PrimeC In ALS Patients; Disease Progression Was Slowed By 36% V Placebo

Benzinga ·  Jul 1 08:03
NeuroSense Reports Results From 12-Month Analysis Of Its PARADIGM Phase 2b Study Evaluating PrimeC In ALS Patients; Disease Progression Was Slowed By 36% V Placebo
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment